Bevantolol Explained

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.[1] [2] It was discovered and developed by Warner-Lambert[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"[4] it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.[5]

Notes and References

  1. Frishman WH, Goldberg RJ, Benfield P . Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris . Drugs . 35 . 1 . 1–21 . January 1988 . 2894292 . 10.2165/00003495-198835010-00001 .
  2. Vaughan Williams EM . Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions . Journal of Clinical Pharmacology . 27 . 7 . 450–60 . July 1987 . 2888789 . 10.1002/j.1552-4604.1987.tb03049.x . 72749127 .
  3. Book: McPherson. Edwin M. . vanc . Pharmaceutical Manufacturing Encyclopedia.. 2007. Elsevier. Burlington. 9780815518563. 618–619. 3rd.
  4. News: Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds. Pink Sheet. 30 January 1989.
  5. Wong GW, Boyda HN, Wright JM . Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension . The Cochrane Database of Systematic Reviews . 3 . CD007451 . March 2016 . 4 . 26961574 . 6486283 . 10.1002/14651858.CD007451.pub2 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bevantolol".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.